breast cancer - adjuvant | breast cancer - HER2-positive | |
breast cancer - adjuvant | la/mBC - HER2 positive - 1st Line (L1) | |
pertuzumab based treatment | ||
pertuzumab plus trastuzumab | APHINITY | PERTAIN |
pertuzumab plus trastuzumab plus docetaxel | PUFFIN CLEOPATRA |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -